Aptorum Group Ltd - Ordinary Shares - Class A

Aptorum Group Ltd. is a pharmaceutical company, which engages in the discovery, development, and commercializing of therapeutic assets to treat diseases with unmet medical needs. It operates through the Therapeutics and Non-Therapeutics segments. The Therapeutics segment seeks to develop drug molecules and certain technologies for the treatment and diagnosis of human disease conditions. The Non-Therapeutics segment encompasses diagnostics projects including a novel molecular-based rapid pathogen identification and detection diagnostics, AML Clinic, and sale of natural supplements. Its pipeline include Smart-Act, Acticule, RPIDD, Nativus, and Claves series. The company was founded by Ian Huen on September 13, 2010 and is headquartered in London, the United Kingdom.

NEW YORK & LONDON & PARIS--( BUSINESS WIRE )--Regulatory News:

Aptorum Group Announces Publication of a Co-authored Paper on its PathsDx Technology - a Rapid-Turnaround Low-Depth Unbiased Metagenomics Sequencing Workflow for Liquid Biopsy based Diagnosis of Infectious Diseases on Illumina Platforms

Aptorum Group Limited Announces Results of 2022 Annual General Meeting of Shareholders

Aptorum Group Announces Completion of $3 Million Convertible Note due 2023

Aptorum Group Announces Offering of $3 Million Convertible Note due 2023

ORLANDO, FL / ACCESSWIRE / November 25, 2022 / RedChip Companies will air a new interview Aptorum Group Limited (NASDAQ:APM)(Euronext Paris:APM), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, on The RedChip Money Report® on Bloomberg TV, this Saturday, November 26, at 7 p.m. Eastern Time (ET).

Aptorum Group Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)

Aptorum Announces Publication of a Co-authored Paper on Development and Validation of a Sensitive Liquid Chromatography with Time-Of-Flight Mass Spectrometry Assay for In Vivo Pharmacokinetic Study of Epigallocatechin-gallate octaacetate (Pro-EGCG)

Aptorum Group Limited Received Nasdaq Notification Letter Regarding Bid Price Deficiency

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today announced that it will hold its 2022 annual general meeting of shareholders at its London office located at 4T.07, 17 Hanover Square, Mayfair London, England W1S 1BN at 12:00 noon London Time on Decemb

Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 21, 2022

NEW YORK--(BUSINESS WIRE)--Regulatory News: Aptorum Group Limited (NASDAQ: APM, Euronext Paris: APM) (“Aptorum Group” or the “Company”), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune and infectious diseases, today provided a business update and announced financial results for the six months ended June 30, 2022. “During the first half of 2022, we remained focused on advancing the development of our therapeutic programs. As announced i

Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2022

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group”), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics to tackling unmet medical needs, announces the commercial launch of NativusWell®, a new dietary supplement supporting women's health throughout the Menopausal period. NativusWell® is distributed via HKTV Mall and NativusWell® official website https://nativuswell.com/ by

Aptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopause, in Hong Kong

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) a clinical stage biopharmaceutical company dedicated to tackling unmet medical needs in oncology, autoimmune diseases and infectious diseases, is pleased to announce further updates on the analytical and both the retrospective and prospective clinical validation of the RPIDD technology in patient samples, employed under both Illumina iSeq 100 and MiniSeq sequencing platforms1. R

Aptorum Group Updates on the Clinical Validation of RPIDD Infectious Disease Liquid Biopsy Molecular Diagnostics

vTv Therapeutics

Yatra Online

Zynex Inc

In general, finding small-cap stocks to buy can be somewhat fraught. These are stocks with market capitalizations between roughly $300 million and $2 billion.

7 Hot Small-Cap Stocks to Buy in September

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today announced that Mr. Darren Lui, CEO and Executive Director of Aptorum Group will present both in-person and virtually at the H.C. Wainwright Global Investment Conference, New York, being held on September 13-16, 2022. Aptorum Group management will be

Aptorum Group Limited to Present at the H.C. Wainwright Annual Global Investment Conference, September 13-16, 2022

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today announced that Mr. Darren Lui, President and Executive Director of Aptorum Group will present virtually at the H.C. Wainwright Global Investment Conference being held on May 23-26, 2022. Aptorum Group management will be available and

Aptorum Group Limited to Present at the H.C. Wainwright Global Investment Conference, May 23 – 26 2022

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #Neuroblastoma--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, is pleased to announce the finalized data from the Phase 1 clinical trial of SACT-1, a repurposed small molecule drug targeting Neuroblastoma and potentially other cancer types. Following the announcement of the Phase 1 clinical trial of SACT-1 in January 2022, Aptorum is pleased to announce further data

Aptorum Group Updates on Data from the Completed Phase 1 Clinical Trial of SACT-1, targeting neuroblastoma

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #Neuroblastoma--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “We”), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today announced financial results for the fiscal year ended December 31, 2021, and provided an update on clinical and corporate developments. Mr. Ian Huen, Chief Executive Officer and Executive Director of Aptoru

Aptorum Group Limited Reports 2021 Fiscal Year End Financial Results and Provides Business Update

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #biopharmaceutical--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, is pleased to announce that the US Patent and Trademark Office (“US PTO”) has granted the patent regarding the Rapid Pathogen Infectious Disease Liquid Biopsy Diagnostics (“RPIDD”) regarding the invention of an unbiased and simultaneous amplification method for DNA library preparation (US Patent No : US1

First Patent Regarding RPIDD Infectious Disease Liquid Biopsy Technology DNA Library Preparation and Amplification Methods Granted

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology and infectious diseases, today announced that an interview with President Mr. Darren Lui will air on The RedChip Money Report® on Bloomberg TV, April 23, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the

Aptorum Group Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report®

Aptorum Group is advancing therapeutic programs to serve unmet needs in orphan oncology diseases, infectious diseases, metabolic diseases, women's health and other areas.

Aptorum Group: Advancing Oncology, Autoimmune & Infectious Disease Therapies

Gran Tierra Energy

NGL Energy Partners

OPKO Health

4 penny stocks outperforming Facebook Meta stock today The post 4 Penny Stocks To Buy For Under $5 Outperforming FB Stock In 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Penny Stocks To Buy For Under $5 Outperforming FB Stock In 2022

The stock price of Aptorum Group Ltd (NASDAQ: APM) increased by over 34% during intraday trading today. This is why it happened.

Aptorum Stock (APM): Why The Price Surged Up Today

APM stock is skyrocketing on Tuesday following news of an FDA designation. Does this mean the meme stocks crazy isn't over?

APM Stock Alert: What Is Going on With Little-Known Aptorum Today?

The stock price of Aptorum Group Ltd (NASDAQ: APM) increased 38.52% today. This is why it happened.

Aptorum Stock (APM): Why The Price Surged Today

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #Neuroblastoma--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, is pleased to announce that the United States Food and Drug Administration (FDA) Office has granted Orphan Drug Designation to SACT-1, a repurposed small molecule compound for the treatment of patients with Neuroblastoma. Aptorum Group plans to file an Investigational New Drug Application (IND) to commen

Aptorum Group Receives FDA Orphan Drug Designation for its SACT-1 Repurposed Drug For The Treatment of Neuroblastoma

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, is pleased to announce that the US Patent and Trademark Office has granted the first patent regarding Aptorum's SACT-1 repurposed drug for the treatment of various cancers including but not limited to neuroblastoma (US Patent 11,166,962 B2). The SACT-1 invention provides a composition and method for trea

News for Aptorum Group Ltd - Ordinary Shares - Class A Stock (APM)